Understanding immune responses to cytomegalovirus after liver transplants
Immune signatures of CMV disease risk after orthotopic liver transplant
This study is looking at how the immune system reacts to a virus called cytomegalovirus (CMV) in people who get liver transplants from donors who have the virus, to help find ways to predict and prevent related health issues after the transplant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11098250 on NIH RePORTER |
What this research studies
This research investigates how the immune system responds to cytomegalovirus (CMV) in patients who receive liver transplants from CMV-infected donors. It focuses on identifying immune factors that can predict the risk of developing CMV-related diseases, such as pneumonia or retinitis, after transplantation. By analyzing blood samples from transplant recipients, the study aims to find markers that indicate a patient's risk level for CMV disease, which could help tailor preventive treatments. The approach includes monitoring immune cell responses and antibody levels in patients over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are undergoing or have recently undergone orthotopic liver transplantation from CMV-infected donors.
Not a fit: Patients who have not received a liver transplant or those who are not at risk for CMV infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing CMV disease in liver transplant recipients, enhancing their overall health outcomes.
How similar studies have performed: Previous research has shown promising results in understanding immune responses to CMV in transplant patients, suggesting that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Ford, Emily — University of Washington
- Study coordinator: Ford, Emily
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.